XL-protein gets European patent for PASylation technology
XL-protein took over worldwide rights for PASylation technology under a license agreement signed with TUM via Bayerische Patentallianz in 2009. The new patent covers covers the use of
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
The clinical trial will be conducted in Hospital Universitario Puerta de Hierro de Majadahonda in Madrid and Clinica Universidad de Navarra in Pamplona. According to researchers at the